PTGX Stock Overview
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases.
Protagonist Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.81|
|52 Week High||US$50.54|
|52 Week Low||US$7.87|
|1 Month Change||-55.84%|
|3 Month Change||-67.80%|
|1 Year Change||-71.09%|
|3 Year Change||-18.50%|
|5 Year Change||-16.81%|
|Change since IPO||-24.70%|
Recent News & Updates
Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
Celebrations may be in order for Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders, with the analysts...
|PTGX||US Biotechs||US Market|
Return vs Industry: PTGX underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: PTGX underperformed the US Market which returned -10.4% over the past year.
|PTGX Average Weekly Movement||17.8%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: PTGX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: PTGX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics Fundamentals Summary
|PTGX fundamental statistics|
Is PTGX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PTGX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.52|
|Net Profit Margin||-261.21%|
How did PTGX perform over the long term?See historical performance and comparison
Is Protagonist Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PTGX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PTGX's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: PTGX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: PTGX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PTGX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PTGX's PB Ratio (1.4x) is in line with the US Biotechs industry average.
How is Protagonist Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PTGX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PTGX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PTGX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PTGX's revenue (66.6% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: PTGX's revenue (66.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PTGX is forecast to be unprofitable in 3 years.
How has Protagonist Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PTGX is currently unprofitable.
Growing Profit Margin: PTGX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PTGX is unprofitable, and losses have increased over the past 5 years at a rate of 25.2% per year.
Accelerating Growth: Unable to compare PTGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PTGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: PTGX has a negative Return on Equity (-40.59%), as it is currently unprofitable.
How is Protagonist Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: PTGX's short term assets ($341.5M) exceed its short term liabilities ($43.5M).
Long Term Liabilities: PTGX's short term assets ($341.5M) exceed its long term liabilities ($3.1M).
Debt to Equity History and Analysis
Debt Level: PTGX is debt free.
Reducing Debt: PTGX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PTGX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PTGX has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 32.4% each year.
What is Protagonist Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PTGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PTGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PTGX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PTGX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PTGX has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dinesh Patel (64 yo)
Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer and President at Protagonist Therapeutics, Inc. since December 2008 and was its Interim Chief Financial Officer till May 28, 2019. Dr. Patel...
CEO Compensation Analysis
Compensation vs Market: Dinesh's total compensation ($USD5.54M) is above average for companies of similar size in the US market ($USD2.65M).
Compensation vs Earnings: Dinesh's compensation has increased whilst the company is unprofitable.
Experienced Management: PTGX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: PTGX's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.7%.
Protagonist Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Protagonist Therapeutics, Inc.
- Ticker: PTGX
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$428.661m
- Shares outstanding: 48.66m
- Website: https://www.protagonist-inc.com
Number of Employees
- Protagonist Therapeutics, Inc.
- 7707 Gateway Boulevard
- Suite 140
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.